Clinical Study of BYM338 for the Treatment of Unintentional Weight Loss in Patients With Cancer of the Lung or the Pancreas

Completed · Phase 2 · Has a placebo group

Conditions studied: Cachexia

In brief

A safety \& efficacy clinical study of the investigational medicinal product BYM338 for the treatment of unintentional weight loss in patients with cancer of the lung or the pancreas

Key facts

Study ID

NCT01433263

Run by

Novartis Pharmaceuticals

People needed

57

Starts

2011-08-01

Expected to finish

2014-04-01

Last updated by the study team

2016-03-02

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Novartis Investigative Site — Tucson, Arizona, United States
• Novartis Investigative Site — Tampa, Florida, United States
• Novartis Investigative Site — Chicago, Illinois, United States
• Novartis Investigative Site — Boston, Massachusetts, United States
• Novartis Investigative Site — Canton, Ohio, United States
• Novartis Investigative Site — San Antonio, Texas, United States
• Novartis Investigative Site — Vilnius, Lithuania
• Novartis Investigative Site — Bucharest, Romania
• Novartis Investigative Site — Sankt Gallen, Switzerland
• Novartis Investigative Site — Edinburgh, United Kingdom

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.